How do you manage painful (non-sbrt) bone metastases in patients receiving nivolumab or other immunotherapy?

Patients on immune checkpoint inhibitors are at risk of developing serious adverse effects from the agents themselves, which can impact on the delivery of radiation. For example, they can develop an immune mediated colitis, which can mimic acute radiation enteritis, but the management is completely ...

We routinely radiate patients receiving Nivolumab without special consideration, given published evidence of no increase in toxicities between patients receiving Nivolumab and those receiving Nivolumab + RT (https://www.ncbi.nlm.nih.gov/pubmed/30202808). Use beam arrangements to avoid organ irradiat...